gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

N-acetyltransferase 2

NAT2, N-acetyltransferase 2
This gene encodes an enzyme that functions to both activate and deactivate arylamine and hydrazine drugs and carcinogens. Polymorphisms in this gene are responsible for the N-acetylation polymorphism in which human populations segregate into rapid, intermediate, and slow acetylator phenotypes. Polymorphisms in this gene are also associated with higher incidences of cancer and drug toxicity. A second arylamine N-acetyltransferase gene (NAT1) is located near this gene (NAT2). [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: Arylamine N-Acetyltransferase, GSTM1, HAD, CYP1A1, GSTT1
Papers on NAT2
Active cigarette smoking and the risk of breast cancer at the level of N-acetyltransferase 2 (NAT2) gene polymorphisms.
Danko et al., Bratislava, Slovakia. In Tumour Biol, Jan 2016
UNASSIGNED: The aim of our study was to assess the correlation between the tobacco exposure and NAT2 gene (rs1041983 C/T, rs1801280 T/C, rs1799930 G/A) polymorphisms in association with breast cancer development.
Omega-3 Fatty Acids and Age-Related Macular Degeneration.
Delcourt et al., Manchester, United Kingdom. In Ophthalmic Res, Dec 2015
Epidemiological studies had indicated potential preventative effects of omega-3, and an earlier randomised prospective study (NAT2) showed that patients who achieved high red blood cell membrane EPA/DHA (eicosapentaenoic acid/docosahexaenoic acid) levels were significantly protected against AMD compared with those with permanently low EPA/DHA levels.
[The role of pharmacogenomics in the tuberculosis treatment regime].
Tarazona et al., Lima, Peru. In Rev Peru Med Exp Salud Publica, Dec 2015
Drug metabolism is directly related to the genetic variation of NAT2 and CYP2E1 (associated with INH metabolism) and AADAC (associated with RIF metabolism), and the effects produced in an individual may be a fast, intermediate or slow metobolizer.
Association Between N-acetyltransferase 2 Polymorphism and Bladder Cancer Risk: Results From Studies of the Past Decade and a Meta-Analysis.
Lv et al., Changzhou, China. In Clin Genitourin Cancer, Nov 2015
UNASSIGNED: Numerous studies have identified that the slow acetylation status of N-acetyltransferase 2 (NAT2) is associated with an elevated bladder cancer risk.
Pharmacogenetics of isoniazid-induced hepatotoxicity.
Wilffert et al., Yogyakarta, Indonesia. In Drug Metab Rev, May 2015
We selected English articles of studies in human from PubMed up to May 2014 with the keywords pharmacogenetic, isoniazid and hepatotoxicity, N-acetyl transferase 2 (NAT2), CYP2E1 and glutathione S transferase (GST).
Association between N-acetyltransferase 2 polymorphisms and pancreatic cancer risk: a meta-analysis.
Zhou et al., Hangzhou, China. In Genet Mol Res, 2014
N-acetyltransferase 2 (NAT2) is an essential phase II enzyme in the metabolism of aromatic and heterocyclic amines and of hydrazines.
Meta-analysis of the relationship between slow acetylation of N-acetyl transferase 2 and the risk of bladder cancer.
Wang et al., Chengdu, China. In Genet Mol Res, 2014
The incidence of bladder cancer is closely associated with exposure to aromatic amines, that can cause cancer only after metabolic activation regulated by N-acetyl transferase 1 and 2 (NAT1 and NAT2).
Genetic susceptibility in childhood acute leukaemias: a systematic review.
Pombo-de-Oliveira et al., Rio de Janeiro, Brazil. In Ecancermedicalscience, 2014
We observed that the most frequently investigated genes were: NQO1, GSTM1, GSTT1, GSTP1, CYP1A1, NAT2, CYP2D6, CYP2E1, MDR1 (ABCB1), XRCC1, ARID5B, and IKZF1.
Risks on N-acetyltransferase 2 and bladder cancer: a meta-analysis.
Xu et al., Huangshi, China. In Onco Targets Ther, 2014
BACKGROUND: It is known that bladder cancer disease is closely related to aromatic amine compounds, which could cause cancer by regulating of N-acetylation and N-acetyltransferase 1 and 2 (NAT1 and NAT2).
Interaction between Red Meat Intake and NAT2 Genotype in Increasing the Risk of Colorectal Cancer in Japanese and African Americans.
Le Marchand et al., Honolulu, United States. In Plos One, 2014
These compounds require bioactivaction by N-acetyltransferase 2 (NAT2).
[Genotype and phenotype polymorphisms of NAT2 and CYP2E1 in the Han Chinese pediatric population].
Shen et al., Beijing, China. In Zhongguo Dang Dai Er Ke Za Zhi, 2012
The important SNPs of NAT2 and CYP2E1 are predominantly wild genotype in the Han Chinese pediatric population.
Arylamine N-acetyltransferase 1: a novel drug target in cancer development.
Minchin et al., Brisbane, Australia. In Pharmacol Rev, 2012
There are two closely related genes on chromosome 8 that encode the two human arylamine N-acetyltransferases--NAT1 and NAT2.
Polymorphic genes of detoxification and mitochondrial enzymes and risk for progressive supranuclear palsy: a case control study.
Litvan et al., Louisville, United States. In Bmc Med Genet, 2011
Our results show that NAT2 rapid acetylator phenotype is associated with progressive supranuclear palsy, suggesting that NAT2 may be responsible for activation of a xenobiotic whose metabolite is neurotoxic.
A meta-analysis of the relationship between NAT2 polymorphism and colorectal cancer susceptibility.
Liu et al., Chongqing, China. In Medicina (kaunas), 2011
These results of our meta-analysis suggest that there is no overall association between NAT2 polymorphism and CRC susceptibility.[meta-analysis]
N-Acetyltransferase 2 and glutathione s-transferase M1 in colon and rectal cancer cases from an industrialized area.
Geller et al., Dortmund, Germany. In J Toxicol Environ Health A, 2011
In contrast to early studies, in the present study the slow NAT2 status is overrepresented in colon and rectal cases
[Polymorphism in the N-acetyltransferase 2 gene in patients with lung cancer. Short communication].
Szczepulska-Wójcik et al., Warsaw, Poland. In Pneumonol Alergol Pol, 2011
Among patients with small cell lung cancer, there was no predominance of genotype of acetylation, whereas among patients with non-small cell lung cancer predominated NAT2*5/5 and NAT2*5/6 genotypes (slow acetylators).
A genome-wide association study of metabolic traits in human urine.
Nauck et al., München, Germany. In Nat Genet, 2011
Variants at three of these loci have previously been linked with important clinical outcomes: SLC7A9 is a risk locus for chronic kidney disease, NAT2 for coronary artery disease and genotype-dependent response to drug toxicity, and SLC6A20 for iminoglycinuria.
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci.
Chanock et al., Bethesda, United States. In Nat Genet, 2010
validated previous candidate associations for the GSTM1 deletion (P = 4 × 10⁻¹¹) and a tag SNP for NAT2 acetylation status (P = 4 × 10⁻¹¹), and found interactions with smoking in both regions.
Genetic susceptibility to cancer: the role of polymorphisms in candidate genes.
Peters et al., Seattle, United States. In Jama, 2008
P = 1.9 x 10(-14)), NAT2 slow acetylator and bladder cancer (OR, 1.46; 95% CI, 1.26-1.68;
NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
Rothman et al., Bethesda, United States. In Lancet, 2005
An exception could be the association between NAT2 slow acetylation, GSTM1 null genotype, and bladder-cancer risk.
share on facebooktweetadd +1mail to friends